LQVTDSGLYRCVIYHPP |
| Catalog No.GC66404 |
LQVTDSGLYRCVIYHPP is a myeloid cell triggered receptor 1 (TREM-1) inhibitory peptide .
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 887255-16-5
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
LQVTDSGLYRCVIYHPP is a myeloid cell triggered receptor 1 (TREM-1) inhibitory peptide [1]. LQVTDSGLYRCVIYHPP inhibits downstream inflammatory signaling pathways by competitively binding to TREM-1 and blocking its activation, thereby exerting anti-inflammatory effects [2]. LQVTDSGLYRCVIYHPP can be used in the study of infectious diseases, inflammatory diseases and tumor immunoregulation [3].
In macrophages, treatment with LQVTDSGLYRCVIYHPP (50μM; 24h) significantly reduced the relative levels of LPS-stimulated IL-6, TNFα, CD14 and TREM-1 mRNA transcripts [4]. In microglial, LQVTDSGLYRCVIYHPP (10μM; 24h) substantially decreased mRNA levels of proinflammatory cytokines (NLRP3, IL-1β, IL-18, IL-6, CD16, CD32, and iNOS) and chemokines (MCP-1, CXCL-1, and CXCL-2) [5]. In human corneal epithelial cells, LQVTDSGLYRCVIYHPP (50μM; 24h) induced TREM-1 blockage significantly inhibited the production of TNF-α, IL-1β, IL-6, and IL-8 upon A. fumigatus infection THCEs [6].
In mice cerebral ischemia/reperfusion (I/R) model, after pharmacologic inhibition of TREM-1 with synthetic peptide LQVTDSGLYRCVIYHPP (1mg/kg; intranasal administration; 3d), ischemia-induced infarction and neuronal injury were substantially alleviated [5]. Cecal ligation and puncture (CLP)-induced sepsis rat model, LQVTDSGLYRCVIYHPP (3.5mg/kg; iv; single injection) inhibits the elevation of proinflammatory cytokines TNF-α, IL-6, and IL-1β, thereby alleviating systemic and distant inflammatory responses [7]. In subarachnoid hemorrhage model, TREM-1 inhibition with LQVTDSGLYRCVIYHPP (1mg/kg; intranasal administration; 24h) improved neurological deficits, mitigated brain water content, and preserved brain-blood barrier integrity 24h after SAH [8].
References:
[1]. Siskind S, Brenner M, Wang P. TREM-1 modulation strategies for sepsis. Frontiers in Immunology. 2022 Jun 15; 13: 907387.
[2]. Fu L, Han L, Xie C, et al. Identification of extracellular actin as a ligand for triggering receptor expressed on myeloid cells-1 signaling. Frontiers in immunology. 2017 Aug 7; 8: 917.
[3]. Theobald V, Schmitt FC, Middel CS, et al. Triggering receptor expressed on myeloid cells-1 in sepsis, and current insights into clinical studies. Critical Care. 2024 Jan 9; 28(1): 17.
[4]. Liu M, Zhang Y, Xiong JY, et al. Etomidate Mitigates Lipopolysaccharide-Induced CD14 and TREM-1 Expression, NF-κB Activation, and Pro-inflammatory Cytokine Production in Rat Macrophages. Inflammation. 2016 Feb; 39(1): 327-335.
[5]. Xu P, Zhang X, Liu Q, et al. Microglial TREM-1 receptor mediates neuroinflammatory injury via interaction with SYK in experimental ischemic stroke. Cell death & disease. 2019 Jul 19; 10(8): 555.
[6]. Hu LT, Du ZD, Zhao GQ, et al. Role of TREM-1 in response to Aspergillus fumigatus infection in corneal epithelial cells. International Immunopharmacology. 2014 Nov 1; 23(1): 288-293.
[7]. Shi X, Zhang Y, Wang H, et al. Effect of triggering receptor expressed on myeloid cells 1 (TREM-1) blockade in rats with cecal ligation and puncture (CLP)-induced sepsis. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2017 Oct 23; 23: 5049.
[8]. Xu P, Hong Y, Xie Y, et al. TREM-1 exacerbates neuroinflammatory injury via NLRP3 inflammasome-mediated pyroptosis in experimental subarachnoid hemorrhage. Translational Stroke Research. 2021 Aug; 12: 643-659.
| Cell experiment [1]: | |
Cell lines | Macrophages cells |
Preparation Method | The isolated macrophages (1.5×105/mL) were cultured in 96-well plates and treated in triplicate with vehicle, consisting of <0.1% dimethyl sulphoxide (DMSO) incomplete medium (control), 1μg/mL LPS for 48h (LPS group) or1μg/mL LPS for 24h and then with 5 or2.5μM etomidate for another 24h (the L+5E or L+2.5E group, respectively). Etomidate was freshly dissolved in DMSO. Some macrophages were cultured in complete medium without LPS stimulation for 24h and then treated with 5 or 2.5μM etomidate (as the 5E or 2.5E group) and 100ng/mL of LQVTDSGLYRCVIYHPP (as the LQVTDSGLYRCVIYHPP group) for 24h.Some macrophages were treated with 1μg/mL of LPS for 24h and then with 5μM etomidate and/or 50μM of LQVTDSGLYRCVIYHPP or control peptide for another 24h (as the L+5E, L+LQVTDSGLYRCVIYHPP and L+LQVTDSGLYRCVIYHPP+5E groups), respectively. |
Reaction Conditions | 50μM; 24h |
Applications | Treatment with LQVTDSGLYRCVIYHPP significantly reduced the relative levels of LPS-stimulated IL-6, TNFα, CD14 and TREM-1 mRNA transcripts in macrophages. |
| Animal experiment [2]: | |
Animal models | Cecal ligation and puncture (CLP)-induced sepsis rat model |
Preparation Method | Polymicrobial sepsis was induced using the cecal ligation and puncture (CLP). Rat was anesthetized with intraperitoneal injection of 40mg/kg thiopental. A small midline incision was made to expose the cecum through the skin and peritoneum under aseptic conditions. Approximately 1.5cm of the cecal appendage was ligated midway between the cecal base and the distal pole, using 4/0 surgical silk. Then, double punctures were made using an 18-gauge needle and expelling a small amount of feces. After cecum repositioning and skin closure, resuscitation was achieved through subcutaneous injection of 1mL pre-warmed saline (0.9% saline). Normal SD Rats receiving 0.1mL saline (1mg in 0.1mL of saline) served as the normal control group (NC). Rats with sepsis induced by CLP were allocated randomly to received scramble peptide (3.5mg/kg; CLP-Scrambled) or LQVTDSGLYRCVIYHPP (3.5mg/kg; CLP-LQVTDSGLYRCVIYHPP) via the jugular vein. |
Dosage form | 3.5mg/kg; iv; single injection |
Applications | LQVTDSGLYRCVIYHPP inhibits the elevation of proinflammatory cytokines TNF-α, IL-6, and IL-1β, thereby alleviating systemic and distant inflammatory responses. |
References: | |
| Cas No. | 887255-16-5 | SDF | |
| Formula | C89H137N23O25S | M.Wt | 1961.25 |
| Solubility | DMso : 25 mg/mL (12.75 mM; Need ultrasonic)H20 : 5 mg/mL (2.55 mM; ultrasonic and adjust pH to 2 with HCI) | Storage | Store at -20°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.5099 mL | 2.5494 mL | 5.0988 mL |
| 5 mM | 0.102 mL | 0.5099 mL | 1.0198 mL |
| 10 mM | 0.051 mL | 0.2549 mL | 0.5099 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *